Session » Osteoarthritis – Clinical Poster I

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1307

A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain

9:00AM-11:00AM: Abstract Number: 1298

A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1323

Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma

9:00AM-11:00AM: Abstract Number: 1299

Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults

9:00AM-11:00AM: Abstract Number: 1309

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1304

Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis

9:00AM-11:00AM: Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

9:00AM-11:00AM: Abstract Number: 1316

Frail Patients Have Less Pain After Total Hip Replacement

9:00AM-11:00AM: Abstract Number: 1317

Frail Patients Have Worse Function After Total Knee Replacement

9:00AM-11:00AM: Abstract Number: 1319

Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis

9:00AM-11:00AM: Abstract Number: 1318

In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms

9:00AM-11:00AM: Abstract Number: 1320

Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort

9:00AM-11:00AM: Abstract Number: 1303

Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA

9:00AM-11:00AM: Abstract Number: 1312

Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 1310

Osteoarthritis: What’s in a Name?

9:00AM-11:00AM: Abstract Number: 1314

Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1300

Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1311

Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study

9:00AM-11:00AM: Abstract Number: 1305

Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa

9:00AM-11:00AM: Abstract Number: 1301

Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts

9:00AM-11:00AM: Abstract Number: 1313

Readmissions After Staged vs Simultaneous Bilateral Total Knee Replacements (TKR)

9:00AM-11:00AM: Abstract Number: 1315

Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study

9:00AM-11:00AM: Abstract Number: 1306

Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?

9:00AM-11:00AM: Abstract Number: 1326

Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1325

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA

9:00AM-11:00AM: Abstract Number: 1302

Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study

9:00AM-11:00AM: Abstract Number: 1308

Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1327

The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

9:00AM-11:00AM: Abstract Number: 1324

Visceral Fat Deposition Associated with Pain in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1321

What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].